Tarsus Pharmaceuticals Inc (TARS)
39.03
+0.45
(+1.17%)
USD |
NASDAQ |
May 20, 13:56
Tarsus Pharmaceuticals Debt to Equity Ratio: 0.1088 for March 31, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2024 | 0.1088 |
| December 31, 2023 | 0.1514 |
| September 30, 2023 | 0.139 |
| June 30, 2023 | 0.1666 |
| March 31, 2023 | 0.1414 |
| December 31, 2022 | 0.1007 |
| September 30, 2022 | 0.0955 |
| Date | Value |
|---|---|
| June 30, 2022 | 0.087 |
| March 31, 2022 | 0.1286 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Mar 2021
0.1666
Maximum
Jun 2023
0.0861
Average
0.1007
Median
Dec 2022
Debt to Equity Ratio Benchmarks
| Pacira BioSciences Inc | 0.5832 |
| Unicycive Therapeutics Inc | -- |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.00 |
| IGC Pharma Inc | 0.0152 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 349.28M |
| Total Liabilities (Quarterly) | 74.07M |
| Shareholders Equity (Quarterly) | 275.21M |
| Current Ratio | 8.012 |
| Net Debt Paydown Yield | -0.15% |